PDCD1 and neoplasm: Research is currently exploring next-generation TILs, including tumor-infiltrating B cells (TIL-B) and PD-1-inactivated TILs, to optimize their therapeutic efficacy, the development of modified interleukins, such as IL-2 superkines with enhanced affinity for the IL-2 β subunit and IL-15 super agonist complexes, is being investigated to enhance their clinical potential further [163,164,165].